Company insider dossier

CytomX Therapeutics Inc insider intelligence

CTMX filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
28/100

Concentrated distribution

42/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
3 Aug 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • Participation spans 10 named insiders rather than one filing source.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
  • The latest qualifying filing is more than 30 days old.
Conviction28Concentrated distribution
Confidence42Thin evidence
Named insiders10participating in the tape
Controlled events1directional common-share events
Acquisition value$0normalized amount
Disposal value$5.0Knormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

5.694.383.071.760.46 Acquisition · 3 Aug 2026 · Not reportedDisposal · 15 Jun 2026 · $5.0K
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
3.46 USD
One-week move
+11.6%
Four-week move
-8.0%
Fair-value gap
+53.3%
Trend signal
Inactive
Relative strength
-21.6

Directional balance

Controlled event mix

0.0%acquisition
Acquisition events
0
Disposal events
1
Net value
-$5.0K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
008 Jun
815 Jun
022 Jun
029 Jun
006 Jul
013 Jul
120 Jul
027 Jul
203 Aug
010 Aug

Named participants

Insider conviction by person

ASHWORTH, ALANDirector500 events
CARVAJAL, ALEJANDRAChief Legal Officer500 events
FUCHS, CHARLES S.Director500 events
GILBERT, HALLEY EDirector500 events
JONES, ELAINE VDirector500 events
MEYERS, JAMES RDirector500 events
MOHINDRU, MANIDirector500 events
SU, ZHENDirector500 events
YOUNG, MATTHEW P.Director500 events
OGDEN, CHRISTOPHERChief Financial Officer281 events

Evidence quality

Security and transaction context

Common equity2
Equity compensation0
Options and derivatives9
Other securities0

Role architecture

Who is participating

Director8
Other executive2
Finance leadership1

Transaction evidence

Auditable CTMX filing ledger

Showing 1 to 11 of 11.

CARVAJAL, ALEJANDRAChief Legal Officer
AcquisitionOptions and derivatives
450000 sharesStock Option (Right to Buy)
Not reportedContext evidence
CARVAJAL, ALEJANDRAChief Legal Officer
AcquisitionCommon equity
100000 sharesCommon Stock
Not reportedContext evidence
FUCHS, CHARLES S.Director
AcquisitionOptions and derivatives
118000 sharesStock Option (Right to Buy)
Not reportedContext evidence
ASHWORTH, ALANDirector
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
GILBERT, HALLEY EDirector
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
JONES, ELAINE VDirector
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
MEYERS, JAMES RDirector
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
MOHINDRU, MANIDirector
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
SU, ZHENDirector
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
YOUNG, MATTHEW P.Director
AcquisitionOptions and derivatives
59000 sharesStock Option (Right to Buy)
Not reportedContext evidence
OGDEN, CHRISTOPHERChief Financial Officer
DisposalCommon equity
1624 sharesCommon Stock
$5.0KDirectional evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context